Efficacy and Safety of AP 12009 in Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma
Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
In this multinational Phase III study the efficacy and safety of 10 µM AP 12009 is compared
to standard chemotherapy (temozolomide or BCNU or CCNU) in adult patients with confirmed
recurrent or refractory anaplastic astrocytoma (WHO grade III) or secondary glioblastoma (WHO
grade IV).